Liquid Biomarkers in Prostate Cancer Diagnosis: Current Status and Emerging Prospects

Overview

Journal World J Mens Health

Date 2024 May 21

PMID 38772530

Authors

Yutong Liu

Koji Hatano

Norio Nonomura

Affiliations

Soon will be listed here.

Abstract

Prostate cancer (PCa) is a major health concern that necessitates appropriate diagnostic approaches for timely intervention. This review critically evaluates the role of liquid biopsy techniques, focusing on blood- and urine-based biomarkers, in overcoming the limitations of conventional diagnostic methods. The 4Kscore test and Prostate Health Index have demonstrated efficacy in distinguishing PCa from benign conditions. Urinary biomarker tests such as PCa antigen 3, MyProstateScore, SelectMDx, and ExoDx Prostate IntelliScore test have revolutionized risk stratification and minimized unnecessary biopsies. Emerging biomarkers, including non-coding RNAs, circulating tumor DNA, and prostate-specific antigen (PSA) glycosylation, offer valuable insights into PCa biology, enabling personalized treatment strategies. Advancements in non-invasive liquid biomarkers for PCa diagnosis may facilitate the stratification of patients and avoid unnecessary biopsies, particularly when PSA is in the gray area of 4 to 10 ng/mL.

Citing Articles

Advancements in Biomarkers of Prostate Cancer: A Review.

Agbetuyi-Tayo P, Gbadebo M, Rotimi O, Rotimi S Technol Cancer Res Treat. 2024; 23:15330338241290029.

PMID: 39440372 PMC: 11497500. DOI: 10.1177/15330338241290029.

References

Djebali S, Davis C, Merkel A, Dobin A, Lassmann T, Mortazavi A . Landscape of transcription in human cells. Nature. 2012; 489(7414):101-8. PMC: 3684276. DOI: 10.1038/nature11233. View

Pu Y, Li C, Yuan H, Wang X . Identification of prostate cancer specific methylation biomarkers from a multi-cancer analysis. BMC Bioinformatics. 2021; 22(1):492. PMC: 8507340. DOI: 10.1186/s12859-021-04416-w. View

Newcomb L, Zheng Y, Faino A, Bianchi-Frias D, Cooperberg M, Brown M . Performance of PCA3 and TMPRSS2:ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study (PASS). Prostate Cancer Prostatic Dis. 2019; 22(3):438-445. PMC: 6642858. DOI: 10.1038/s41391-018-0124-z. View

Verbeek J, Bangma C, Kweldam C, van der Kwast T, Kummerlin I, van Leenders G . Reducing unnecessary biopsies while detecting clinically significant prostate cancer including cribriform growth with the ERSPC Rotterdam risk calculator and 4Kscore. Urol Oncol. 2018; 37(2):138-144. DOI: 10.1016/j.urolonc.2018.11.021. View

Tutrone R, Donovan M, Torkler P, Tadigotla V, McLain T, Noerholm M . Clinical utility of the exosome based ExoDx Prostate(IntelliScore) EPI test in men presenting for initial Biopsy with a PSA 2-10 ng/mL. Prostate Cancer Prostatic Dis. 2020; 23(4):607-614. PMC: 7655505. DOI: 10.1038/s41391-020-0237-z. View

de la Calle C, Patil D, Wei J, Scherr D, Sokoll L, Chan D . Multicenter Evaluation of the Prostate Health Index to Detect Aggressive Prostate Cancer in Biopsy Naïve Men. J Urol. 2015; 194(1):65-72. PMC: 4696043. DOI: 10.1016/j.juro.2015.01.091. View

Leyten G, Hessels D, Jannink S, Smit F, de Jong H, Cornel E . Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. Eur Urol. 2012; 65(3):534-42. DOI: 10.1016/j.eururo.2012.11.014. View

Ferro M, Bruzzese D, Perdona S, Marino A, Mazzarella C, Perruolo G . Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10 ng/ml. PLoS One. 2013; 8(7):e67687. PMC: 3701535. DOI: 10.1371/journal.pone.0067687. View

Bussemakers M, van Bokhoven A, Verhaegh G, Smit F, Karthaus H, Schalken J . DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res. 1999; 59(23):5975-9. View

10.

Singh N, Ramnarine V, Song J, Pandey R, Padi S, Nouri M . The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer. Nat Commun. 2021; 12(1):7349. PMC: 8692330. DOI: 10.1038/s41467-021-26901-9. View

11.

Bruyere F, Malavaud S, Bertrand P, Decock A, Cariou G, Doublet J . Prosbiotate: a multicenter, prospective analysis of infectious complications after prostate biopsy. J Urol. 2014; 193(1):145-50. DOI: 10.1016/j.juro.2014.07.086. View

12.

Vickers A, Cronin A, Aus G, Pihl C, Becker C, Pettersson K . Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen: data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden. Cancer. 2010; 116(11):2612-20. PMC: 2882167. DOI: 10.1002/cncr.25010. View

13.

Fan Y, Pan P, Cheng W, Wang H, Shen S, Liu H . The Prostate Health Index aids multi-parametric MRI in diagnosing significant prostate cancer. Sci Rep. 2021; 11(1):1286. PMC: 7935887. DOI: 10.1038/s41598-020-78428-6. View

14.

McKiernan J, Donovan M, ONeill V, Bentink S, Noerholm M, Belzer S . A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy. JAMA Oncol. 2016; 2(7):882-9. DOI: 10.1001/jamaoncol.2016.0097. View

15.

Saldova R, Fan Y, Fitzpatrick J, Watson R, Rudd P . Core fucosylation and alpha2-3 sialylation in serum N-glycome is significantly increased in prostate cancer comparing to benign prostate hyperplasia. Glycobiology. 2010; 21(2):195-205. DOI: 10.1093/glycob/cwq147. View

16.

Fujita K, Shimomura M, Uemura M, Nakata W, Sato M, Nagahara A . Serum fucosylated haptoglobin as a novel prognostic biomarker predicting high-Gleason prostate cancer. Prostate. 2014; 74(10):1052-8. DOI: 10.1002/pros.22824. View

17.

Liang C, Qi Z, Ge H, Liang C, Zhang Y, Wang Z . Long non-coding RNA PCAT-1 in human cancers: A meta-analysis. Clin Chim Acta. 2018; 480:47-55. DOI: 10.1016/j.cca.2018.01.043. View

18.

Olleik G, Kassouf W, Aprikian A, Hu J, Vanhuyse M, Cury F . Evaluation of New Tests and Interventions for Prostate Cancer Management: A Systematic Review. J Natl Compr Canc Netw. 2018; 16(11):1340-1351. DOI: 10.6004/jnccn.2018.7055. View

19.

Merola R, Tomao L, Antenucci A, Sperduti I, Sentinelli S, Masi S . PCA3 in prostate cancer and tumor aggressiveness detection on 407 high-risk patients: a National Cancer Institute experience. J Exp Clin Cancer Res. 2015; 34:15. PMC: 4324853. DOI: 10.1186/s13046-015-0127-8. View

20.

Ylitalo E, Thysell E, Landfors M, Brattsand M, Jernberg E, Crnalic S . A novel DNA methylation signature is associated with androgen receptor activity and patient prognosis in bone metastatic prostate cancer. Clin Epigenetics. 2021; 13(1):133. PMC: 8244194. DOI: 10.1186/s13148-021-01119-0. View